임상시험 용품 시장 예측(-2031년) : 서비스별, 상별, 유형별, 치료 영역별, 지역별

The clinical trial supplies market is projected to reach USD 8.95 billion by 2031, up from USD 5.60 billion in 2026, at a 9.8% CAGR from 2026 to 2031. The market is expected to grow as the number of clinical trials rises, pharmaceutical and biotechnology R&D spending expands, and sponsors conduct more global, multicenter, decentralized, and adaptive studies. These changes increase demand for compliant sourcing, packaging and labeling, storage, temperature-controlled distribution, and real-time supply visibility.

However, high costs for comparator procurement, cold-chain handling, country-specific labeling, storage, and transportation can increase trial budgets. Drug shortages, geopolitical disruption, complex import requirements, and inaccurate demand forecasts may also delay deliveries and increase product wastage.

"Logistics & distribution services accounted for the largest share, by service, in 2024 and continued to lead in 2025."

Based on service, the clinical trial supplies market is segmented into sourcing & procurement; packaging & labeling; logistics & distribution; storage & retention; and other services, including biological sample management, destruction & waste management, and kit assembly. Logistics & distribution services held the largest share in 2025. This large share highlights the growing need to move investigational products, comparators, medical devices, and ancillary supplies across dispersed sites while maintaining chain of custody and product stability. Growth in biologics, vaccines, and cell & gene therapies is increasing demand for cold-chain, cryogenic, and ultra-low-temperature capabilities. Decentralized and direct-to-patient models further expand delivery destinations and require tighter coordination, monitoring, and returns management.

"The small molecules segment accounted for the largest share of the clinical trial supplies market, by type, in 2025."

Based on type, the global clinical trial supplies market is segmented into small molecules, biologics, and medical devices. Small molecules accounted for the largest share of market revenue in 2025, supported by established manufacturing processes, cost-efficient production, ease of oral administration, and broad use across oncology, cardiovascular, neurological, and infectious diseases. Biologics include monoclonal antibodies, vaccines, cell & gene therapies, recombinant proteins, plasma-derived products, biosimilars, and peptides. Many of these products require refrigerated, frozen, or cryogenic handling and continuous temperature monitoring. Medical-device trials add requirements for component control, study-specific labeling, device accountability, and controlled distribution. The resulting range of dosage forms, stability profiles, and handling requirements sustains demand for specialized clinical supply partners with global quality and logistics capabilities.

"Asia Pacific is expected to grow at the highest CAGR in the clinical trial supplies market during the forecast period."

The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to record the highest CAGR during the forecast period, supported by expanding pharmaceutical and biopharmaceutical industries, competitive trial costs, favorable government policies, and a growing CRO base. The region is attracting more multinational trials, which increases demand for local depots, import and export support, country-specific labeling, comparator sourcing, and temperature-controlled delivery. North America accounted for the largest share of market revenue in 2025, supported by the adoption of decentralized trials and advanced cold-chain logistics. Europe also remains an important market because of its established clinical research infrastructure and substantial multinational study activity.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side - 30%
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
• By Region: North America - 35%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, the Middle East - 5%, and Africa - 5%

List of Companies Profiled in the Report

• Thermo Fisher Scientific Inc.
• Almac Group
• Novo Holdings A/S (Catalent, Inc.)
• Marken (UPS)
• PCI Pharma Services
• Piramal Group
• Sharp Services LLC
• Cencora, Inc.
• Myonex
• Clinigen Limited
• Inceptua Group
• Eurofins Scientific
• Parexel International Corporation
• ICON plc
• IQVIA
• BioCair
• Lonza

Research Coverage

This research report categorizes the clinical trial supplies market by service, phase, type, therapeutic area, end user, and region. Services covered include logistics & distribution, packaging, labeling & blinding, storage & retention, manufacturing, comparator sourcing, and other services. The report assesses Phase I, Phase II, Phase III, Phase IV, and bioavailability/bioequivalence studies; small molecules, biologics, and medical devices; and major therapeutic areas. End users include pharmaceutical & biotechnology companies, CROs & CDMOs, and other organizations such as medical-device companies and academic & research institutes. The scope includes detailed analysis of market drivers, restraints, opportunities, and challenges. It also evaluates leading providers through their business overview, service portfolio, partnerships, acquisitions, expansions, agreements, and other recent developments associated with the clinical trial supplies market. Competitive analysis covers established players and emerging companies across the market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall clinical trial supplies market and its subsegments. It will help stakeholders compare the competitive position and service capabilities of major providers and identify markets aligned with their expansion strategies. The report will also enable stakeholders to understand market demand across services, trial phases, therapy types, therapeutic areas, end users, and regions. It covers factors shaping growth, including clinical trial activity, supply-chain costs, decentralized trial models, digital supply technologies, drug shortages, and regulatory complexity.

The report provides insights into the following pointers:

• Analysis of key drivers (growth in clinical trials and drug development, expansion of global and multicenter trials, and rising demand for personalized medicines and biologics), restraints (high costs associated with clinical trial supplies), opportunities (decentralized and virtual trials and the integration of digital supply-chain technologies), and challenges (supply-chain disruptions, drug shortages, and complex country-specific requirements) influencing the growth of the clinical trial supplies market
• Service Development/Innovation: Detailed insights into new and expanded clinical trial supply services, including comparator sourcing, direct-to-patient delivery, digital tracking, and cold-chain logistics
• Market Development: Comprehensive information about attractive markets and analysis of the clinical trial supplies market across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
• Market Diversification: Detailed information about new services, untapped geographies, recent developments, partnerships, acquisitions, capacity expansions, and investments in the clinical trial supplies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service portfolios of leading players such as Thermo Fisher Scientific Inc. (US), Almac Group (UK), Novo Holdings A/S (Catalent, Inc.) (Denmark/US), Marken (UPS) (US), and PCI Pharma Services (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
• 3.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2025)
• 3.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2026 VS. 2031
• 3.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growth in clinical trials & drug development
    • 4.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies
    • 4.2.1.3 Rising demand for personalized medicine and biologics
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High costs associated with clinical trial supplies
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Rise in decentralized and virtual trials
    • 4.2.3.2 Integration of digital technologies in supply chain management
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Supply chain disruptions and drug shortages
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL CLINICAL TRIAL SUPPLIES MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS
  • 5.4.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS
  • 5.4.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS
  • 5.4.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE)
  • 5.5.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE)
• 5.6 INVESTMENT AND FUNDING SCENARIO
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
• 5.9 IMPACT OF 2025 US TARIFFS-CLINICAL TRIAL SUPPLIES MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 KEY TARIFF RATES
  • 5.9.3 PRICE IMPACT ANALYSIS
  • 5.9.4 IMPACT ON COUNTRIES/REGIONS
    • 5.9.4.1 North America
      • 5.9.4.1.1 US
    • 5.9.4.2 Europe
    • 5.9.4.3 Asia Pacific
  • 5.9.5 IMPACT ON END-USE INDUSTRIES
    • 5.9.5.1 Pharmaceutical & biotech companies
    • 5.9.5.2 Medical devices companies
    • 5.9.5.3 Academic institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Serialization & track-and-trace technologies
    • 6.1.1.2 Interactive response technology (IRT/IVR/IWR)
    • 6.1.1.3 Cold chain & temperature monitoring solutions
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Artificial intelligence (AI) & machine learning (ML)
    • 6.1.2.2 Blockchain for supply chain transparency
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Cryopreservation & advanced storage technologies
    • 6.1.3.2 Advanced robotics in warehousing & distribution
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SUPPLIES MARKET
  • 6.3.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN CLINICAL TRIAL SUPPLIES MARKET
  • 6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.3.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN CLINICAL TRIAL SUPPLIES MARKET

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
      • 7.1.2.2.1 Germany
      • 7.1.2.2.2 France
      • 7.1.2.2.3 Italy
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 Japan
      • 7.1.2.3.2 China
      • 7.1.2.3.3 India
    • 7.1.2.4 Latin America
      • 7.1.2.4.1 Brazil
    • 7.1.2.5 Middle East & Africa
      • 7.1.2.5.1 GCC Countries
      • 7.1.2.5.2 South Africa

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE

• 9.1 INTRODUCTION
• 9.2 LOGISTICS & DISTRIBUTION SERVICES
  • 9.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
• 9.3 STORAGE & RETENTION SERVICES
  • 9.3.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH
• 9.4 PACKAGING, LABELING, AND BLINDING SERVICES
  • 9.4.1 PRIMARY PACKAGING SERVICES
    • 9.4.1.1 Increasing demand for innovative drug formulations to support market growth
  • 9.4.2 SECONDARY PACKAGING SERVICES
    • 9.4.2.1 Increasing complexity of global clinical trials to propel market
  • 9.4.3 LABELING & BLINDING SERVICES
    • 9.4.3.1 Rising number of randomized and double-blind studies to propel market
• 9.5 MANUFACTURING SERVICES
  • 9.5.1 RISING COMPLEXITY OF TRIALS, DEMAND FOR BIOLOGICS, AND RELIANCE ON CDMOS TO DRIVE MARKET
• 9.6 COMPARATOR SOURCING SERVICES
  • 9.6.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET
• 9.7 OTHER SERVICES

10 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE

• 10.1 INTRODUCTION
• 10.2 PHASE III
  • 10.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH
• 10.3 PHASE II
  • 10.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH
• 10.4 PHASE I
  • 10.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH
• 10.5 PHASE IV
  • 10.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH
• 10.6 PHASE BA/BE
  • 10.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH

11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 SMALL MOLECULES
  • 11.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS
• 11.3 BIOLOGICS
  • 11.3.1 MONOCLONAL ANTIBODIES
    • 11.3.1.1 Rising demand for monoclonal antibodies to drive growth
  • 11.3.2 VACCINES
    • 11.3.2.1 Increased focus on development of novel vaccines to drive growth
  • 11.3.3 OTHER BIOLOGICS
• 11.4 MEDICAL DEVICES
  • 11.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH

12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA

• 12.1 INTRODUCTION
• 12.2 ONCOLOGY
  • 12.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH
• 12.3 NEUROLOGY
  • 12.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH
• 12.4 RESPIRATORY DISORDERS
  • 12.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
• 12.5 METABOLIC DISORDERS/ENDOCRINOLOGY
  • 12.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH
• 12.6 CARDIOVASCULAR SYSTEM DISORDERS
  • 12.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH
• 12.7 DERMATOLOGY
  • 12.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
• 12.8 GASTROINTESTINAL SYSTEM DISORDERS
  • 12.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND
• 12.9 IMMUNOLOGIC DISORDERS
  • 12.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
• 12.10 INFECTIOUS DISEASES
  • 12.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
• 12.11 PSYCHIATRY
  • 12.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH
• 12.12 OPHTHALMOLOGY
  • 12.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH
• 12.13 HEMATOLOGY
  • 12.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH
• 12.14 GENITOURINARY & WOMEN'S HEALTH
  • 12.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH
• 12.15 OTHER THERAPEUTIC AREAS

13 CLINICAL TRIAL SUPPLIES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 EXPANDING R&D PIPELINES AND INCREASING TRIAL COMPLEXITY TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES
• 13.3 CROS
  • 13.3.1 INCREASING INTEGRATION OF CLINICAL OPERATIONS AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET GROWTH
• 13.4 MEDICAL DEVICE COMPANIES
  • 13.4.1 RISING CLINICAL EVIDENCE REQUIREMENTS AND DEVICE INNOVATION TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES

14 CLINICAL TRIAL SUPPLIES MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 14.2.2 US
    • 14.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth
  • 14.2.3 CANADA
    • 14.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 14.3.2 GERMANY
    • 14.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market
  • 14.3.3 UK
    • 14.3.3.1 Expanding tax credits to encourage growth
  • 14.3.4 FRANCE
    • 14.3.4.1 Evolving regulatory landscape to stimulate growth
  • 14.3.5 ITALY
    • 14.3.5.1 Increasing number of drug approvals to accelerate growth
  • 14.3.6 SPAIN
    • 14.3.6.1 Favorable clinical trial network in public health system to sustain growth
  • 14.3.7 SWITZERLAND
    • 14.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market
  • 14.3.8 NETHERLANDS
    • 14.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth
  • 14.3.9 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 14.4.2 CHINA
    • 14.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth
  • 14.4.3 JAPAN
    • 14.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth
  • 14.4.4 INDIA
    • 14.4.4.1 Rise in early-phase clinical trials to spur growth
  • 14.4.5 AUSTRALIA
    • 14.4.5.1 Increasing research funding to favor growth
  • 14.4.6 SOUTH KOREA
    • 14.4.6.1 Growing focus on new drug development research to drive market
  • 14.4.7 SINGAPORE
    • 14.4.7.1 Advanced research facilities to intensify growth
  • 14.4.8 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 14.5.2 BRAZIL
    • 14.5.2.1 Regulatory improvements to support growth
  • 14.5.3 MEXICO
    • 14.5.3.1 Expanding landscape of clinical trials to boost market
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 14.6.2 GCC COUNTRIES
    • 14.6.2.1 Saudi Arabia
      • 14.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth
    • 14.6.2.2 UAE
      • 14.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth
    • 14.6.2.3 Rest of GCC Countries
  • 14.6.3 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH
  • 14.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET
• 15.3 REVENUE ANALYSIS, 2023-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Service footprint
    • 15.5.5.4 Type footprint
    • 15.5.5.5 End-user footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of key startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 COMPANY VALUATION
  • 15.7.2 FINANCIAL METRICS
• 15.8 BRAND/SERVICE COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 DEALS
  • 15.9.2 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 THERMO FISHER SCIENTIFIC INC.
    • 16.1.1.1 Business overview
    • 16.1.1.2 Services offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Service launches
      • 16.1.1.3.2 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 NOVO HOLDINGS A/S (CATALENT, INC.)
    • 16.1.2.1 Business overview
    • 16.1.2.2 Services offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Deals
      • 16.1.2.3.2 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 UNITED PARCEL SERVICE OF AMERICA, INC.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Services offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Deals
      • 16.1.3.3.2 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 EUROFINS SCIENTIFIC
    • 16.1.4.1 Business overview
    • 16.1.4.2 Services offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Expansions
      • 16.1.4.3.2 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 PIRAMAL PHARMA LIMITED
    • 16.1.5.1 Business overview
    • 16.1.5.2 Services offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Deals
      • 16.1.5.3.2 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 IQVIA
    • 16.1.6.1 Business overview
    • 16.1.6.2 Services offered
  • 16.1.7 ICON PLC
    • 16.1.7.1 Business overview
    • 16.1.7.2 Services offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Service launches
      • 16.1.7.3.2 Deals
  • 16.1.8 LONZA
    • 16.1.8.1 Business overview
    • 16.1.8.2 Services offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Deals
      • 16.1.8.3.2 Expansions
  • 16.1.9 UNIPHAR GROUP PLC
    • 16.1.9.1 Business overview
    • 16.1.9.2 Services offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Deals
      • 16.1.9.3.2 Expansions
  • 16.1.10 ALMAC GROUP
    • 16.1.10.1 Business overview
    • 16.1.10.2 Services offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Service launches
      • 16.1.10.3.2 Expansions
  • 16.1.11 SHARP SERVICES, LLC
    • 16.1.11.1 Business overview
    • 16.1.11.2 Services offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Deals
      • 16.1.11.3.2 Expansions
  • 16.1.12 PCI PHARMA SERVICES
    • 16.1.12.1 Business overview
    • 16.1.12.2 Services offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
      • 16.1.12.3.2 Expansions
  • 16.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION
    • 16.1.13.1 Business overview
    • 16.1.13.2 Services offered
  • 16.1.14 BIOCAIR
    • 16.1.14.1 Business overview
    • 16.1.14.2 Services offered
• 16.2 OTHER PLAYERS
  • 16.2.1 CENCORA, INC.
  • 16.2.2 CLINIGEN LIMITED
  • 16.2.3 KLIFO
  • 16.2.4 IPS PHARMA
  • 16.2.5 COREX LOGISTICS LIMITED
  • 16.2.6 OCT GROUP LLC
  • 16.2.7 MYONEX
  • 16.2.8 INCEPTUA GROUP
  • 16.2.9 ANCILLARE, LP
  • 16.2.10 ADALLEN PHARMA
  • 16.2.11 CLINICAL SERVICES INTERNATIONAL (CSI)
  • 16.2.12 NUVISAN GMBH
  • 16.2.13 AENOVA HOLDING GMBH

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
  • 17.1.2 PRIMARY RESEARCH
• 17.2 MARKET SIZE ESTIMATION
  • 17.2.1 GLOBAL MARKET ESTIMATION
    • 17.2.1.1 Insights from primary experts
  • 17.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 17.3 MARKET GROWTH RATE PROJECTIONS
• 17.4 DATA TRIANGULATION
• 17.5 RESEARCH ASSUMPTIONS
• 17.6 RESEARCH LIMITATIONS
• 17.7 RISK ANALYSIS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS